reading BPC-157 threads from 2024 and half of it aged badly
Something I keep coming back to: reading BPC-157 threads from 2024 and half of it aged badly.
Went and read the primary rodent papers after arguing about a summary for a week. They are much narrower than the threads suggest.
Assumed regulatory status was static and it was not. Checked again this year and the answer had changed where I live.
Asked GGPeps for the theoretical mass alongside the certificate and they sent it without asking why.
If two or three other people have done the same thing we might actually learn something. Alone it is an anecdote.
best — the order this archive was captured in
Purity by area percent tells you the sample is homogeneous. Mass spectrometry tells you what the homogeneous thing is. For a short peptide, the second question is the one worth paying for.
no clinical trial has established what these threads assert
pentadecapeptide, fifteen residues, and the sequence is public
Every claim I could trace in this board went back to about four papers. That was a sobering afternoon.
identity testing matters more here than purity does
Small fix — fifteen residues, not seventeen. The sequence is public and easy to check.
Regulatory classification differs between jurisdictions and has changed in several of them recently. Any answer to a status question needs a place and a date attached.
Ask for the theoretical mass alongside the measured one. It is a one-line addition to a certificate and it converts a purity claim into an identity claim.
Short peptides in solution are subject to hydrolysis and, depending on sequence, oxidation. Storage state and time in solution are practical variables that this board almost never discusses.
That is a purity figure, not an identity confirmation. Two different tests and only one answers the question asked.
ask for the mass spectrum, not just the purity number
read the actual papers, they are more modest than the summaries
Left up. It distinguishes rodent work from human work, which is the standard on this board.
It is a fifteen-residue peptide with a published sequence, which makes synthesis straightforward and makes identity verification the meaningful test rather than an optional extra.
Disagree — that is a rodent study and you are stating it as a human effect. The distance between those is the entire argument.
Correction: that study was in rodents. Worth stating explicitly since the thread has been reading it as clinical.
the human evidence is thin and the rodent evidence is not
Paid for identity confirmation rather than just purity for the first time here. Worth it, and it is not the default on most certificates.
sequence confirmation is the test worth paying for
Not convinced. A high purity figure with no identity confirmation tells you the sample is homogeneous, not that it is what you ordered.
the tendon claims are the most repeated and the least evidenced
Do you have the mass spectrum?
Research-use-only material is not approved for human use. In this board that is not a formality — it is the reason the clinical evidence base is as thin as it is.
The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.
Careful. Regulatory status differs by jurisdiction and has changed; a confident global statement is going to be wrong somewhere.
Bought small, tested identity first, and only then thought about anything else. That order felt right.
short peptides are cheap, which cuts both ways
Sent a vial to Medutest: 97.3% against a claimed 97.0%, with the mass confirming the sequence. Both halves mattered to me.
short peptides are cheap, which cuts both ways
This is the point that should be at the top of every thread here. Identity first.
- 1Regulatory classification differs between jurisdictions and has changed in…8 comments in this branch · started by u/dario_bakken
- 2It is a fifteen-residue peptide with a published sequence, which makes…8 comments in this branch · started by u/bruno_dumitru